Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Myotonic Dystrophy Type 1 Clear all

Conditions: Breast Cancer
Interventions: Trastuzumab, Paclitaxel, Trastuzumab emtansine; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 85
States / cities: Birmingham, Alabama • San Francisco, California • Hartford, Connecticut + 62 more

Conditions: Myotonic Dystrophy Type 1
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab emtansine [Kadcyla]; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: Not listed
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 40
States / cities: Little Rock, Arkansas • Denver, Colorado • Washington D.C., District of Columbia + 34 more

Conditions: Advanced Breast Cancer
Interventions: PD-0332991 and T-DM1; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer
Interventions: Trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: Fort Myers, Florida • Lafayette, Indiana • Scarborough, Maine + 11 more

Conditions: HER2-positive Breast Cancer
Interventions: tucatinib, placebo, T-DM1; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 321
States / cities: Mobile, Alabama • Gilbert, Arizona • Goodyear, Arizona + 180 more

Conditions: Myotonic Dystrophy Type 1
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Docetaxel, Pertuzumab, Trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Charlotte, North Carolina • Houston, Texas

Conditions: Metastatic Solid Tumor, Brain Metastases
Interventions: Trastuzumab emtansine, Tucatinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myotonic Dystrophy
Interventions: Mexiletine, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions: T-DM1, Pertuzumab, Excision of tumor/mastectomy; Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 4
States / cities: Boston, Massachusetts • Nashville, Tennessee

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Abemaciclib, Trastuzumab Emtansine; Drug · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Yuma, Arizona • Jacksonville, Florida • Urbana, Illinois + 3 more

Conditions: DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonic Dystrophy Type 1, Myotonic Dystrophy Type-1, Myotonic Dystrophy, Type 1 (DM1), Myotonic Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Breast Cancer
Interventions: T-DM1; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 60 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 14
States / cities: Duarte, California • Stamford, Connecticut • Boston, Massachusetts + 10 more

Conditions: Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER 2 Low-expressing Breast Cancer
Interventions: [68Ga]Ga-ABY-025; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
Interventions: AOC 1001, Placebo; Drug
Lead sponsor: Avidity Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more

Conditions: Prostatic Neoplasms
Interventions: MLN2704 (DM1 conjugated monoclonal antibody MLN591); Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 4
States / cities: New York, New York • Durham, North Carolina • Cleveland, Ohio

Conditions: Breast Cancer
Interventions: DS-8201a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 36
States / cities: Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 26 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
Interventions: Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment; Biological · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2035
U.S. locations: 1160
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more

Conditions: Congenital Myotonic Dystrophy, CDM
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Up to 59 Months
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Fairway, Kansas • Rochester, New York + 1 more

Conditions: Myotonic Dystrophy Type 1 (DM1), DM1
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 88 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Congenital Myotonic Dystrophy, Childhood Myotonic Dystrophy, Myotonic Dystrophy
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 3 Years to 17 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Little Rock, Arkansas • Kansas City, Kansas • Richmond, Virginia

Conditions: Breast Cancer, HER2-positive Breast Cancer
Interventions: trastuzumab-emtansine, Trastuzumab SC, Paclitaxel; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 53
States / cities: San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 44 more

Conditions: Myotonic Dystrophy Type 1
Interventions: IONIS-DMPKRx, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 8
States / cities: Stanford, California • Gainesville, Florida • Kansas City, Kansas + 5 more

Search by objective public record fields.

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Metabolomic Biomarkers of Myotonic Dystrophy

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

DMCRN-02-001: Assessing Pediatric Endpoints in DM1

Remote Assessments and Genetic Determinants of Myotonic Dystrophy

Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension

ATEMPT 2.0: Adjuvant T-DM1 vs TH

A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1